<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The development of <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> may be influenced by hormonal, immunomodulatory, and metabolic pathways </plain></SENT>
<SENT sid="1" pm="."><plain>Prolactin (PRL), ferritin, <z:chebi fb="27" ids="27300">vitamin D</z:chebi>, and the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> marker tissue <z:chebi fb="1" ids="15841">polypeptide</z:chebi> antigen (<z:chebi fb="6" ids="15702,53394">TPA</z:chebi>) were measured in <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo>: <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE), systemic <z:mp ids='MP_0000612'>sclerosis</z:mp> (SSc), <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> (RA), <z:e sem="disease" ids="C0085655" disease_type="Disease or Syndrome" abbrv="">polymyositis</z:e> (PM), <z:e sem="disease" ids="C0011633" disease_type="Disease or Syndrome" abbrv="">dermatomyositis</z:e> (DM), multiple <z:mp ids='MP_0000612'>sclerosis</z:mp> (MS), autoimmune <z:hpo ids='HP_0000820'>thyroid diseases</z:hpo>, and <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000870'>Hyperprolactinemia</z:hpo> (HPRL) was detected in 24% of PM patients, in 21% of SLE patients, in 6.7% of MS patients, 6% of RA patients, and in 3% of SSc patients </plain></SENT>
<SENT sid="3" pm="."><plain>Hyperferritinemia was detected in 23% of SLE patients, 15% of DM patients, 8% of MS patients, and 4% of RA patients </plain></SENT>
<SENT sid="4" pm="."><plain>The patients had relatively low levels of 25 OH <z:chebi fb="27" ids="27300">Vitamin D</z:chebi>: the average results (mean +/- SD) were between 9.3 +/- 4.4 to 13.7 +/- 7.1 ng/mL in the different diseases, while the 25 OH <z:chebi fb="27" ids="27300">Vitamin D</z:chebi> concentrations less than 20 ng/mL are regarded as deficient </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="6" ids="15702,53394">TPA</z:chebi> levels were in the same range of the controls, elevated only in SLE </plain></SENT>
<SENT sid="6" pm="."><plain>HPRL, hyperferritinemia, <z:e sem="disease" ids="C1510471" disease_type="Disease or Syndrome" abbrv="">hypovitaminosis</z:e> D, and <z:chebi fb="6" ids="15702,53394">TPA</z:chebi> levels did not correlate with SLE activity elevated levels of rheumatoid factor or anti-<z:chebi fb="97" ids="35889">CCP</z:chebi> antibodies in RA </plain></SENT>
<SENT sid="7" pm="."><plain>HPRL, hyperferritinemia, and <z:e sem="disease" ids="C1510471" disease_type="Disease or Syndrome" abbrv="">hypovitaminosis</z:e> D have different immunological implications in the pathogenesis of the <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Preventive treatment with <z:chebi fb="27" ids="27300">vitamin D</z:chebi> or therapy for HPRL with <z:chebi fb="0" ids="51065">dopamine agonists</z:chebi>, may be considered in certain cases </plain></SENT>
<SENT sid="9" pm="."><plain>Hyperferritinemia may be used as an <z:hpo ids='HP_0011009'>acute</z:hpo>-phase reactant marker in <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> mainly SLE </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="6" ids="15702,53394">TPA</z:chebi> may be used to indicate the tendency for <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
</text></document>